Compare Abeona Therapeutics Inc (ABEO) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs National Beverage Corp. — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while National Beverage Corp. trades at $32.71 (market cap $3.04B). The key difference: National Beverage Corp. is far larger — about 8.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| ABEO | FIZZ | |
|---|---|---|
Market Cap | $373.32M | $3.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $47.69 |
52-Week Low | $4.17 | $31.00 |
Enterprise Value | $228.22M | $2.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FIZZ (National Beverage Corp.) trades at $32.48, down 2.55% today, with a bearish technical signal and mixed earnings performance. The company maintains strong profitability with 15.56% net margin and 34.03% ROE, though revenue has stagnated around $1.2B annually. Recent news highlights a special $3.25 dividend announcement that boosted shares despite three consecutive quarterly earnings misses.
Outlook remains cautious with 50% of analysts rating Sell amid competitive pressures and consumer weakness. The dividend provides shareholder return but earnings consistency remains a concern. Key risks include tariff impacts and market saturation, while current valuation multiples appear reasonable given profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
